中/EN: 中文繁體 English

Investor Relations
IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
Corporate

Press Releases

2021

Please select

AUG
27

The United Laboratories International Holdings Limited, Announces 2021 Interim Results, Profit Attributable to Shareholders up by 207.2% to RMB623.1 Million Insulin Series Products Maintained Steady Growth, Successfully Delivered First Batch of Insulin Aspart Products

JUL
15

TUL Receives Drug Registration Approval for Insulin Aspart, Enriching Portfolio of Diabetic Drugs

MAR
30

The United Laboratories International Holdings Limited, Announces 2020 Annual Results, Profit attributable to Shareholders up by 9.5% to RMB703 Million, Insulin Series Beat Sales Targets